Good news! -Biotest Hangzhou Future Science and Technology City New Park opening

2022-01-14

With the continuous increase of business and the continuous growth of the company's team, in order to better serve customers, increase production capacity, and improve the production environment, Biotest Biotech officially opened the new park of Hangzhou Future Science and Technology City recently. The park was built at the end of 2018, covers an area of 23,000 square meters, and consists of multiple functional areas such as production area, office area, and storage area. The relocation of the new park of the Science and Technology City will be fully completed, In the future, Biotest will thrive.

 

On November 15, 2021, Biotest Biotech held a grand entrance ceremony in the new park. Mr. Yinlong Chen, Chairman of Biotest said at the ceremony: The opening of the new park marks a new chapter for Biotest. All employees of Biotest Bio will continue to uphold the spirit of struggle, quality and innovation, start from the new, set sail from the new, overcome obstacles all the way, go forward courageously, and create new brilliance!

At 11 o'clock in the morning, the chairman of Biotest , together with the main management team and the guests present, officially cut the ribbon for the new park. This marks that Biotest has entered a new stage of development after successfully logging on to the Sci-tech Innovation Board in September 2021.

It has been more than ten years since Biotest was established, and the original Zhongtai Park has gradually been unable to meet the requirements of the company's development. In the new park, the hardware environment of the factory has been improved, which greatly enhances Biotest's market competitiveness. In order to build an intelligent integrated production workshop, the company introduced multiple sets of automated production equipment, and intelligently upgraded the internal ERP system and warehousing logistics management system, which greatly improved the efficiency of production and logistics. It is estimated that after the completion of the transformation, Biotest will be able to increase its production capacity by 400 million people/year, which will provide a strong guarantee for the company's future development. The company will take the opportunity of entering the new park to further optimize the work process, and through the continuous pursuit of R&D, production, operational efficiency and sales coverage, to provide higher quality, innovative and competitive products and services for the Chinese and global markets.

 

 

About Biotest:

 Founded in 2008, Biotest is a high-tech enterprise specializing in R&D, manufacturing, sales and services of in vitro diagnostic reagents. Biotest is committed to providing innovative, immediate and high-quality diagnostic products and solutions to meet the unfulfilled medical needs and to provide the most cost-effective rapid in vitro diagnostic products and services to global users.

At present, Biotest has more than 100 kinds of products, and its business covers more than 100 countries and regions around the world, serving more than 3 billion people.


Please fill in your contact information
and your needs